Gene Editing, Biotechnology, and Precision Medicine by Beam Therapeutics

  • Andreas Kristo
  • 23.07.2026
Beam Therapeutics stock drops 2.49 percent as BeamTx shares hiring update amid weak momentum
Beam Therapeutics is seeking an Associate Director or Director of Toxicology to join its Non-Clinical Development team.The company says it is looking for candidates who want to be part of a ...
  • Emilio Ghigini
  • 01.07.2026
Beam Therapeutics stock holds at $34.25 as BeamTx celebrates 9-year anniversary in Cambridge and Durham
Beam Therapeutics marked its 9-year anniversary with celebrations in Cambridge, Massachusetts and Durham, North Carolina.Beam Therapeutics stated that the #BeamTeam gathered to kick off summer and ...
  • Ezequiel Gomes
  • 09.06.2026
Beam Therapeutics stock trades up to $29.67 as BeamTx welcomes new summer interns
Beam Therapeutics welcomed its newest class of interns this summer. The company shared the announcement on social media.Beam Therapeutics stated it looks forward to hearing the perspectives of the ...
  • Sholanke Dele
  • 04.06.2026
Beam Therapeutics stock edges higher 2.04% after award recognition, Beam Therapeutics notes
Beam Therapeutics received the 2026 Life Sciences Award from Triangle Business Journal, with the honor formally presented at the company's North Carolina office by a representative from Senator ...
  • Andreas Kristo
  • 06.11.2025
Beam Therapeutics achieves top CGT award for BEAM-302
Beam Therapeutics has been awarded the Overall CGT Solution of the Year for its alpha-1 antitrypsin deficiency program, BEAM-302. This recognition comes from the esteemed BioTech Awards, ...